Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

The p21 data from the early cohorts are supposed to be "unimpressive" because the primary objective is safety, so the dosing levels are a lot lower than the expected therapeutic range. P21 activation from the early cohorts, no matter the amount, is significant because it is starting to align with the xenografted animal models. This critical piece of information often gets overlooked by investors.

Half of the pts showing little change is unimpressive.

Kevetrin is expected to be effective against 50% of the cancers, not 100%.

or maybe you'd like to address the other half that presumably showed no change.